About Us
We concentrate on cancers and other high-incidence diseases to fulfill numerous unmet medical needs. Our particular expertise is in Androgen Receptor related diseases
Including prostate cancer, breast cancer, liver cancer, COVID-19, alopecia, acne and other diseases that not only affect a large number of patients but also lack effective treatments
Our diverse product pipeline is built on a foundation of internal R&D and supplemented with external licensing. We are committed to provide the best therapeutics for our patients
Small-molecule innovative drugs
The product pipeline primarily focuses on AR antagonists and was subsequently expanded to include mTOR inhibitors, Hedgehog inhibitors, AR protein degradation agents and cMyc inhibitors.
Innovative biologics
Our first novel biologic drug, an ALK-1 antibody licensed from Pfizer, is expected to become a "first-in-class" biologic for multiple cancers. From this project , Kintor biologics start to layout in the biologics area.
Combination therapy
In order to provide the best treatment plan for prostate cancer, breast cancer, liver cancer and other deseases, we are creating diverse combination therapies with our own innovative drugs at core.
Our Platform
R&D Platform
We have established a globally integrated R&D platform covering multi-disciplinary fields such as medicinal chemistry, biology, pharmacology, toxicology and clinical research. These multi-dimensional and efficient operations have greatly enriched the company's product pipeline and accelerated the research and development of the product.
Manufacturing Base
A modern pharmaceutical manufacturing base in Suzhou which covers an area of about 20,000 ㎡ has been completed following GMP standards and will be ready for production in 2020.
Commercial Operation
In anticipation of the commercial launch of both the tumor and hair loss products, the company is building an independent marketing team based on a carefully considered overall market and commercialization strategy. Our goal is to build a compliant, professional, and efficient business operation team before our innovative product launch.
R&D Platform
We have established a globally integrated R&D platform covering multi-disciplinary fields such as medicinal chemistry, biology, pharmacology, toxicology and clinical research. These multi-dimensional and efficient operations have greatly enriched the company's product pipeline and accelerated the research and development of the product.
Manufacturing Base
A modern pharmaceutical manufacturing base in Suzhou which covers an area of about 20,000 ㎡ has been completed following GMP standards and will be ready for production in 2020.
Commercial Operation
In anticipation of the commercial launch of both the tumor and hair loss products, the company is building an independent marketing team based on a carefully considered overall market and commercialization strategy. Our goal is to build a compliant, professional, and efficient business operation team before our innovative product launch.
News Center
2021-02-22
Completion of Patients’Recruitment for Proxalutamide’s COVID-19 Hospitalised Study
2021-02-18
Kintor‘s GT90001 and Nivolumab Combination Therapy Obtains Approval of Phase II Clinical Trial from US FDA for the Second-Line Treatment of Advanced Hepatocellular Carcinoma
2021-02-02
Kintor’s GT20029 IND for PROTAC AR Degrader Was Accepted by NMPA
Talent Recuritment
Copyright: Kintor Pharmaceutical Limited retains all copyrights. 苏ICP备19028699号-2 Powered by 300.cn
Complaints and Suggestions Tel: +86 512 62639935 Email: public@kintor.com.cn